Skip to content

Study of an application-delivered mindfulness-based intervention to manage fear of progression for patients with hematologic malignancies

Study of an application-delivered mindfulness-based intervention to manage fear of progression for patients with hematologic malignancies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090963
Enrollment
Unknown
Registered
2024-10-16
Start date
2023-01-08
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignacies

Interventions

intervention group (mindfulness + usual care):On the basis of usual care, the researchers organized the implementation of offline group mindfulness intervention courses during the patients hospitaliza
control group (usual care):Usual nursing was provided, including psychological nursing, dietary guidance, intravenous catheterization nursing, and related health education after chemotherapy, etc. At

Sponsors

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. Patients with hematologic malignancies, including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome, who meet the diagnostic criteria of the International Classification of Diseases (ICD-10); 2. At least 1 month or more of chemical treatment; 3. Age =18 years old, male or female; 4. Fear of Disease Progression Scale (FOP-Q-SF) =34 points; 5. The patient is expected to survive for more than 3 months; 6. The patient knows the condition; 7. The patient himself or under the guidance of family members skilled use of smart phones; 8. Voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous psychiatric history, severe cognitive impairment and mental illness; 2. Severe visual, auditory, and language impairment; 3. Accompanied by serious physical disease or other tumors; 4. The patient is in critical condition and cannot cooperate with the researcher.

Design outcomes

Primary

MeasureTime frame
fear of disease progression;

Secondary

MeasureTime frame
resilience;quality of life;

Countries

China

Contacts

Public ContactLi Junjie

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

lijunjie@ihcams.ac.cn+86 137 5230 2179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026